The acceleration of global biopharmaceutical manufacturing capabilities has driven an unprecedented wave of innovation within the chronic metabolic care sector. For decades, standard care relied on treating isolated biological markers, but contemporary clinical methodologies recognize that metabolic dysfunction is a deeply systemic issue. This realization has forced global research...